Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ronald Davis

Neurology with Special Qualifications in Child Neurology Winter Park, FL Medical Doctor

NPI 1396792024 CMS profile 290284

1245 W Fairbanks Ave Ste 305, Winter Park, FL 32789

Open in the dashboard

General payments

$153,529

394 records reported · program years 2019–2025

Research payments

$1,212

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$719,665 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Ronald Davis of Winter Park, FL is reported in the CMS Open Payments database as having received $153,529 across 394 general payments and $1,212 in research payments paid to them. Separately, studies naming them as principal investigator received $719,665 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,064 41
2024 General $24,401 61
2023 General $36,806 89
2022 General $29,644 67
2022 Research $297 1
2021 General $11,520 30
2021 Research $765 2
2020 General $10,798 21
2020 Research $150 1
2019 General $34,297 85

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ronald Davis
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Ronald Davis were reported at $6,064. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Ronald Davis Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $34,297 $262 $68–$1,313 $163
2020 $10,798 $188 $46–$1,222 $114
2021 $11,520 $183 $45–$1,356 $132
2022 $29,644 $229 $72–$1,177 $149
2023 $36,806 $269 $93–$1,195 $160
2024 $24,401 $300 $98–$1,428 $164
2025 $6,064 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. UCB, Inc. $72,762 174 payments
  2. LivaNova USA, Inc. $29,369 53 payments
  3. Eisai Inc. $23,703 57 payments
  4. Neurelis, Inc. $9,557 21 payments
  5. Jazz Pharmaceuticals Inc. $6,274 19 payments
  6. Biocodex, Inc. $4,521 4 payments
  7. UCB Biosciences Inc. $1,750 1 payment
  8. Otter Pharmaceuticals, LLC $1,366 2 payments
  9. Zogenix Inc. $1,000 1 payment
  10. Greenwich Biosciences, Inc. $801 5 payments
  11. Other $2,427 57 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $94,271 54 payments
  2. Consulting Fee $25,321 12 payments
  3. Travel and Lodging $19,433 105 payments
  4. Food and Beverage $9,848 220 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $3,156 2 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $1,500 1 payment
Products named General payments · program years 2019–2025
  1. Fintepla $73,300 155 payments
  2. Fycompa $23,703 57 payments
  3. VNS Therapy $20,045 39 payments
  4. VALTOCO $9,557 21 payments
  5. Epidiolex $7,075 24 payments
  6. VNS THERAPY SENTIVA MODEL 1000 GENERATOR Neurology $5,311 10 payments
  7. DIACOMIT $4,521 4 payments
  8. VNS THERAPY SENTIVA MODEL 1000 GENERATOR Cardiology/Vascular Diseases $2,484 2 payments
  9. VNS - Sentiva $1,529 2 payments
  10. SYMPAZAN $1,366 2 payments
  11. Other $2,601 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $1,212 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

40

Median for Psychiatry & Neurology: 100

Drug cost

$84,229

Median for Psychiatry & Neurology: $2,986

Branded share of claims

35%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Epidiolex Cannabidiol (Cbd) Brand 14 $77,372
Lacosamide Generic 12 $6,174
Levetiracetam Generic 14 $682

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Fintepla
  • UCB, Inc. $19,397
$19,397 — —
SYMPAZAN
  • Otter Pharmaceuticals, LLC $1,338
$1,338 — —
Epidiolex
  • JAZZ PHARMACEUTICALS INC. $81
$81 14 —
Qelbree
  • Supernus Pharmaceuticals, Inc. $80
$80 — —
DIACOMIT
  • BIOCODEX, INC. $72
$72 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

398 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record